Achilles therapeutics appoints james taylor as chief business officer and cassian yee, md to scientific advisory board

London, june 30, 2022 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing precision t cell therapies to treat solid tumors, today announced the appointment of james taylor as chief business officer and cassian yee, md to its scientific advisory board (sab), effective july 1, 2022.
ACHL Ratings Summary
ACHL Quant Ranking